Skip to content

Roche bladder cancer med too costly for routine use: UK

August 2, 2017

Britain’s healthcare cost-effectiveness agency NICE has decided Roche’s new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.

The National Institute for Health and Care Excellence (NICE) said the drug was not cost-effective for patients who had received chemotherapy, but it might be worth giving to untreated patients or those who cannot have cisplatin-based chemotherapy.

NICE, which decides if medicines should be used on the state health service, urged Roche to submit a proposal for Tecentriq to be used under the Cancer Drugs Fund (CDF), which would allow the collection of more evidence in this setting.

The CDF offers an alternative source of funding and is designed to provide access to promising treatments.

http://reut.rs/2u6mVBP

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: